Clinical studies in melanoma
The NeoLIPA clinical study:
This is an investigator-initiated clinical study (PI: Henrik Jespersen, Department of Oncology) to test intratumoral injections of the oncolytic peptide LTX-315 in combination with the immune checkpoint inhibitor pembrolizumab (anti-PD1) as neoadjuvant treatment for stage III melanoma. The study is conducted in collaboration with Lytix Biopharma (https://www.lytixbiopharma.com/) and includes an extensive portfolio of translational studies to search for biomarkers and mechanisms of action. The study commenced Q4 2024 and will include 27 patients.